- Home
- RAPT
as 11-14-2025 3:40pm EST
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 498.4M | IPO Year: | 2019 |
| Target Price: | $57.00 | AVG Volume (30 days): | 778.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.67 - $42.39 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RAPT Therapeutics Inc. News
RAPT Breaking Stock News: Dive into RAPT Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
How Recent Developments Are Shaping the Randoncorp Investment Story
GlobeNewswire
9 days ago
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
GlobeNewswire
11 days ago
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
MT Newswires
11 days ago
Tetra Tech Wins 5-Year, $249 Million US Army Corps of Engineers Contract for Water Management
MT Newswires
11 days ago
Scotiabank Adjusts Equity Residential Price Target to $66 From $73, Maintains Sector Perform Rating
MT Newswires
11 days ago
DMG Blockchain Solutions Announces Asset Purchase to Establish its First US-based Data Center; Announces October Preliminary Operational Results
Verdict Food Service
11 days ago
Toast and Uber agree multi-year partnership for restaurants
MT Newswires
11 days ago
Jefferies & Co Adjusts Willis Towers Watson Price Target to $400 From $399, Maintains Buy Rating
Compare RAPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RAPT RAPT Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.